Search results
Showing 1636 to 1650 of 9128 results
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over (TA1157)
Evidence-based recommendations on givinostat (Duvyzat) for treating Duchenne muscular dystrophy in people 6 years and over.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)
Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia in adults.
Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment in adults.
Sotatercept for treating pulmonary arterial hypertension (TA1161)
Evidence-based recommendations on sotatercept (Winrevair) for pulmonary arterial hypertension in adults.
Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.
Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation) (TA1180)
NICE is unable to make a recommendation on netarsudil (Rhokiinsa) for treating open-angle glaucoma or ocular hypertension in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1180
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer (TA1177)
Evidence-based recommendation on pembrolizumab (Keytruda) with chemoradiotherapy for untreated locally advanced cervical cancer in adults.
Show all sections
Evidence-based recommendations on deuruxolitinib (Leqselvi) for treating severe alopecia areata in adults.
NICE is unable to make a recommendation on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer in adults who have had anti-androgen treatment but have not had a taxane. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1179
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis (TA1155)
Evidence-based recommendations on rozanolixizumab (Rystiggo) for treating antibody-positive generalised myasthenia gravis in adults.
Evidence-based recommendation on mirvetuximab soravtansine (Elahere) for treating folate receptor-alpha (FR-alpha)-positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.
Evidence-based recommendations on ceritinib (Zykadia) for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have had crizotinib.